全髋关节置换术中混合使用不同厂商组件的注册数据分析
基于美国关节置换注册系统2012至2021年65岁以上初次全髋关节置换患者数据。共纳入434985例,其中混合厂商组件占5%。混合使用率从2012年不足2%升至2021年近17%。校正混杂后,混合与匹配组件在全因翻修及无菌性松动、感染、不稳、假体周围骨折翻修风险上均无差异。
要点
- 混合厂商组件使用率从2012年不足2%增至2021年近17%。
- 混合组件组更常用双动轴承和三锥度股骨柄设计。
- 校正后混合与匹配组全因翻修风险无差异(HR 1.0,95%CI 0.9-1.1)。
核心结论
- 初次全髋关节置换术中混合使用不同厂商组件与匹配组件相比,早期翻修风险无差异。
研究设计与样本
- 回顾性队列研究,使用美国全国注册系统数据,纳入2012至2021年65岁以上初次全髋关节置换且随访至少2年的患者。
- 共434985例,匹配组件413607例(95%),混合组件21378例(5%)。
- 采用病因特异性Cox模型分析全因翻修及无菌性松动、感染、不稳、假体周围骨折翻修风险。
主要发现
- 混合组件使用率从2012年不足2%上升至2021年近17%(P < 0.001)。
- 混合组件组双动轴承使用率27%(4956例)对比匹配组7%(24631例),P < 0.001。
- 混合组件组三锥度股骨柄使用率18%(7185例)对比匹配组9%(27987例),P < 0.001。
- 校正混杂后,全因翻修HR 1.0(95%CI 0.9-1.1),无菌性松动翻修HR 1.2(95%CI 0.9-1.6),感染翻修HR 1.2(95%CI 0.9-1.4),不稳翻修HR 1.0(95%CI 0.8-1.2),假体周围骨折翻修HR 0.9(95%CI 0.7-1.2)。
- 两组无翻修生存时间无差异。
临床怎么用
- 在全髋关节置换术中,混合使用不同厂商的股骨和髋臼组件未显示增加早期翻修风险。
- 临床决策时可考虑组件匹配性,但混合使用并非早期翻修的独立危险因素。
局限性
- 研究为回顾性注册数据分析,可能存在未测量的混杂因素。
- 仅纳入65岁以上患者,结论外推至年轻患者需谨慎。
- 随访时间至少2年,缺乏长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As implants in primary total hip arthroplasty (THA) continue to evolve, surgeons may elect to combine femoral and acetabular components from different manufacturers. However, the prevalence of mixing implants in contemporary hip arthroplasty is unknown, as is the consequence that this may or may not have on implant survival. METHODS: A nationwide registry was used to select patients 65 years or older who underwent primary THA between 2012 and 2021 and who had a minimum 2-year follow-up to create a retrospective cohort comparison of patients who had matched versus mixed manufacturer components. A total of 434,985 cases were identified [matched: 413,607 (95%), mixed: 21,378 (5%)]. The unadjusted and adjusted risk of all-cause revision, as well as revision for aseptic loosening, infection, instability, and periprosthetic fracture, were modeled with cause-specific Cox models. RESULTS: Mixing THA components increased over time from less than 2% of cases in 2012 to nearly 17% in 2021 (P < 0.001). The mixed cohort more commonly utilized dual mobility bearings (27%, 4,956 versus 7%, 24,631; P < 0.001) and triple-tapered femoral stem designs (18%, 7,185 versus 9%, 27,987; P < 0.001). After controlling for potential confounding variables, there was no difference between the two groups in terms of all-cause revision (hazard ratio (HR) 1.0, 95% confidence interval (CI) 0.9 to 1.1), revision for aseptic loosening (HR 1.2, 95% CI 0.9 to 1.6), revision for infection (HR 1.2, 95% CI 0.9 to 1.4), revision for instability (HR 1.0, 95% CI 0.8 to 1.2), or revision for periprosthetic fracture (HR 0.9, 95% CI 0.7 to 1.2). There was no difference in revision-free survival time between groups. CONCLUSION: Mixing implants from different manufacturers in primary THA does not result in an associated difference in the risk of early revision between mixed versus matched manufacturer components.
引用
- Kirchner GJ, Zaniletti I, De A, et al. Mixing Components From Different Manufacturers in Total Hip Arthroplasty: An Analysis of the American Joint Replacement Registry. J Arthroplasty. 2026. PMID: 41638519. doi:10.1016/j.arth.2026.01.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。